Login to Your Account

Vertex, Merck Form Potential $384M Cancer Deal For VX-680

By Karen Pihl-Carey

Wednesday, June 23, 2004
In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription